Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $19.50 Consensus PT from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $19.50.

Several brokerages recently issued reports on ZVRA. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. Maxim Group upped their price objective on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. William Blair reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Monday, April 1st.

Zevra Therapeutics Stock Up 1.3 %

NASDAQ:ZVRA opened at $4.81 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market capitalization of $208.90 million, a P/E ratio of -3.73 and a beta of 1.87. The company’s 50-day simple moving average is $5.46 and its 200-day simple moving average is $5.36. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $7.28.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.20). The firm had revenue of $13.22 million during the quarter, compared to analyst estimates of $13.35 million. Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%. On average, equities analysts anticipate that Zevra Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. Janney Montgomery Scott LLC raised its stake in shares of Zevra Therapeutics by 1.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after buying an additional 9,062 shares during the last quarter. Retirement Planning Co of New England Inc. purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter worth about $1,674,000. Armistice Capital LLC purchased a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $1,755,000. Mystic Asset Management Inc. acquired a new position in Zevra Therapeutics in the 3rd quarter worth about $980,000. Finally, Bank of New York Mellon Corp acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $977,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.